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Abstract 
 
Canine dilated cardiomyopathy (DCM) is a lethal myocardial disease prevalent in 
large and giant-sized dog breeds, including the Great Dane (GD). The goal of this 
study was to identify genetic risk factors for DCM and to contribute to a future 
development of DCM genetic markers in order to facilitate disease diagnosis and 
risk allele detection. Furthermore, in the long term, the identification of novel 
genes and pathways that may contribute for development of future therapies. 
Two different approaches of genome wide association study (GWAS) using data 
from ~170,000 Single Nucleotide Polymorphism (SNP) markers were conducted 
in order to identify disease-associated regions of the genome. A previous GWAS 
to this study used a different cohort of individuals and analytical software. This 
methodology detected six candidate regions on chromosomes 3, 16, 19, 29 and 
30 (two associated regions on chr19). The current GWAS tested nine different 
models in a dataset containing 127 Great Danes (62 cases and 65 controls). The 
GenABEL package for R was used for the analysis. The elected model 3 
included population stratification and had an inflation factor lambda (λ) equal to 
1.04. Two regions on chromosome 19 overlapped with the first GWAS. Region 1: 
between 23-23.3 Mb containing two rRNAs; Region 2: between 44-46Mb 
containing three genes: SPOPL, NXPH2 and a LRP1B orthologue. No marker 
reached Bonferroni statistical significance, and the low power could be due to 
insufficient number of cases and controls. It is suggested that SNP typing of extra 
Great Danes and a better use of the available phenotype data would help to 
improve the statistical power. The correction for complex gene-gene interactions 
such as epistasis may be an interesting approach to detect novel candidates. 
The regions detected in the precedent GWAS were re-sequenced using Illumina 
Next generation sequencing technology in five animals (three controls and two 
cases), and the data was available for analysis in the current study. Six 
candidate non-synonymous mutations were detected in the DMXL2, TMC3, 
ZMAT4, MESDC2 genes and in a paralogue to RPL10A. DMXL2 encodes for a 
protein important for the Notch pathway in mammals. In humans, a SNP in this 
gene has been associated with ischemic stroke. The polymorphism in DMXL2 
was confirmed through the genotyping of 319 individuals and the non-reference 
allele is slightly more frequent on verified cases as opposed to verified controls, 
however, the difference is not statistically significant (t-test p-value= 0.366; 2X3 
Fisher test p-value= 0.258). Further analysis on both regions on chr19 should be 
carried out in order to detect possible novel mutations, copy number variants, 
genes and regulatory elements that could influence the DCM phenotype. 
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1. Introduction 
 
Dilated cardiomyopathy (DCM) is a myocardial disease that affects different 
species including dogs (Canis familiaris). Several authors describe DCM 
pathology, and it generally consists of cardiac dilatation with atrio-ventricular 
incompetence and congestive heart failure; and consequently due to 
compensatory mechanisms: pulmonary edema, pleural effusion and ascites [1-4]. 
The prognosis is poor hence an affected dog has a ~34% chance of surviving 
one year after the initial diagnosis, with a median of only 126 days according to a 
retrospective study of 62 dogs [2]. Histopathologically there are two described 
types of DCM with probable different etiologies: attenuated wavy fiber type and 
fatty infiltration-degenerative type. The  “wavy fiber type” is the most commonly 
found in dogs [4].  
DCM in dogs has an overall prevalence of approximately 0.5%. It affects mostly 
pedigree dogs (0.65%) compared with crossbreeds (0.16%). Dogs from large- 
and giant-sized breeds are the most predisposed to the disease, including the 
Great Danes, Newfoundlands, Boxers, Irish Wolfhounds and Doberman 
Pinschers among others [5]. In this study we focus on Great Danes (GD) and it is 
the second most commonly affected dog breed with a clinical prevalence of 
3.9%[5]. The DCM epidemiology facts suggest that even though the disease 
etiology is highly influenced by environmental factors (e.g. nutritional 
deficiencies), there is also a strong genetic factor underlying this pathology. 
There is also an apparent sex predisposition as male dogs are affected more 
often than female dogs [6]. The pedigree analysis of 17 Great Danes done by 
Meurs et al. [7] has suggested that DCM in Great Danes has a X-linked 
recessive mode of inheritance, which could resemble the X-linked DCM in 
humans. However, an autosomal recessive mode of inheritance hasn’t been 
ruled out, therefore the type of inheritance for this particular breed is still 
unknown [7]. 
There are several DCM candidate genes and loci across breeds, but so far no 
actual causative mutations have been confirmed. The criteria for determination of 
candidate genes are generally based on (1) molecular information from a similar 
disease in a unique species such as human or mouse; (2) the prevalence of the 
candidate gene in a tissue of interest (myocardium, valve, etc); or (3) the specific 
function of the gene (i.e., structural protein, involved in channel regulation, 
etc)[8]. In humans, many causative genes have been identified, and these genes 
appear to encode mutant proteins of the cytoskeleton, sarcolemma and 
sarcomere, ion channels and transcription factors.  [9-10]. Gene mutations in the 
lamin (LMNA) gene are the most prevalent in humans, and more than 20 other 
genes have been implicated in DCM etiology: myosin heavy chain (MYH7); 
troponin (TNNT2 and TNNC2); actin (ACTC1 and ACTN2); dystrophin (DMD) 
genes and others. The mode of inheritance in familial dilated cardiomyopathy in 
humans varies, and it can be autosomal dominant (most common), autosomal 
recessive or X-linked [10]. Mutations in critical cytoskeletal proteins such as 
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metavinculin VCL, α-dystroglycan DAG1, α and γ- sarcoglycan SGCA and 
SGCG, and muscle LIM protein may also result in DCM. The canine homologues 
for each of these structural protein genes are potential candidates for canine 
DCM in general. In a study carried out by Wiersma et al., an evaluation of 15 
candidate genes was made in four Newfoundland dog families [3]. Candidates 
like TNNT2 and LMNA were not associated to DCM, suggesting that the genetic 
cause of DCM for this dog breed may be different from the currently known 
mutations in humans and experimental models of disease [3]. This might also be 
the case for the Great Danes. Several candidate genes were proposed for GD 
DCM by previous studies, but confirmed causative mutations have yet to be 
described. For example, Oyama et al. conducted a transcriptional study where 
they analyzed gene expression patterns of left ventricular tissue samples using 
three Great Dane dogs with end-stage DCM, and three large breed control dogs 
[11-12]. The study demonstrated that Great Danes with DCM showed an 
abnormal castalbin2 and triadin expression, exposing the ryanodine receptor 2 
(RYR2) gene as a candidate. Another expression study using two Doberman 
Pinschers with end-stage DCM and five healthy dogs, identified 478 transcripts 
that were differentially expressed (≥ 2.5 fold change). The identified transcripts 
were divided in groups that revealed that pathways involving cellular energy 
production, signaling and communication, and cell structure were downregulated, 
whereas pathways involving cellular defense and stress responses were 
upregulated [12]. This represents how complex the DCM trait is, and that 
compensatory mechanisms and regulatory mutations are no less important than 
causative structural mutations. 
More recently with the rapid advances in sequencing technology, the detection of 
candidate genes and associated regions got a whole new approach. High-
resolution single nucleotide polymorphism (SNP) arrays allow the mapping of the 
whole genome for many individuals simultaneously. When whole genome and 
good phenotypic data information is available, it is now possible to detect 
differences in the genome between cases and controls. This gives the 
opportunity to find novel genes and mutations that may contribute to a better 
understanding of the pathology not only in the dog but also in all species affected 
by the disease.  
Genome-wide association studies (GWAS) have been shown to be an efficient 
method to identify candidate genes for mono- and polygenetic diseases [13]. The 
dog is an optimal species when it comes to GWAS, and that is because it 
possess a large extent of linkage disequilibrium (LD) within dog breeds 
(distances of several megabases) and between breeds there is a shorter LD 
(over tens of kilobases) [14]. Because of this, as few as 10,000-30,000 SNPs are 
sufficient for a GWAS in the dog [15].  
Based on this background, a GWAS was performed using the high density 
~170,000 SNP array in 127 Great Danes (62 cases and 65 controls). A 
precedent GWAS detected six candidate regions in Great Danes (in 
chromosomes 3, 16, 19, 29 and 30). Two candidate regions were present on 
chromosome 19. All these associated regions were then re-sequenced by 
Illumina Next generation sequencing technology.  
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In the present study, a GWAS using different individuals was run. Two different 
datasets were used and in total nine different models were tested; the variables 
of the models included affection status (case or control), gender (male or 
female), population stratification and kinship matrix. A dataset including all 127 
animals and a separated male dataset to examine the X chromosome was used, 
with the expectation of increasing the reliability of the associated regions 
detected in the previous analysis. Furthermore, the Illumina sequences of the 
candidate regions from the previous GWAS were analyzed in order to detect 
genetic variants between the affected and control Great Dane dogs that could be 
functional causative mutations. 
The goal of this study was to contribute to the future development of GD DCM 
markers in order to facilitate its diagnosis, and risk assessment. In addition, the 
long-term goal is to identify novel genes and pathways that may contribute for a 
better understanding of the disease etiology, and for the development of future 
therapies. 
 
2. Materials and methods 
 
2.1. GWAS analysis:  
The genotype data was obtained from an Illumina 170k SNP assay of 127 
individuals (62 cases and 65 controls) from 7 different countries (24 from 
Sweden, 49 Germany, 12 Holland, 7 USA, 19 UK, 1 Finland, 1 France and 4 
unknown). The criteria to determine which animals are cases and controls was 
based on proposed guidelines for DCM diagnosis [5]:  
 
(1) DCM, verified PAD: The dog was diagnosed after autopsy and histological 
examination of myocardium; 
(2) DCM, CHF:  The dog's medical history was consistent with DCM and had 
developed clear signs of heart failure and pulmonary edema, and ascites 
leverstas;  
(3) DCM, verified echo: The diagnosis was confirmed by ultrasound, according to 
a standardized method developed specifically for the disease [5];  
 
Two different phenotypical datasets (Appendix 1) were analyzed using the 
GenABEL package (http://www.genabel.org/) [16-17] for the RStudio™ open 
source integrated development environment for R. The datasets and had 
different analytical purposes:  
Dataset 1: 127 animals (62 cases and 63 controls) and (74 males and 53 
females);  
Dataset 2: 67 individuals, all males (44 cases and 23 controls).  
The purpose of dataset 1 was to include as many animals as possible to test for 
association significance on autosomal markers. The dataset 2 allowed testing 
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markers on the X chromosome. The phenotype data input contained information 
such as animal ID, gender (male or female) and affected status (case or control). 
The data went through two quality controls:  
Quality Control 1:  Preliminary control in order to remove markers with call rate (< 
0.95); markers with minor allele frequency (MAF<10-8); markers which are very 
strongly out of Hardy-Weinberg equilibrium (p-level <10-8) and individuals with 
more than 5% missing genotypes.   
Quality Control 2: Eliminates markers that are out of Hardy-Weinberg equilibrium 
in a more strict approach. In this quality control, the rate of unacceptably high 
individual heterozygosity false discovery rate (FDR <0.2) was considered. This 
was applied only within the control group, because in cases the deviation can be 
the actual signal. 
Statistical models: An exploratory analysis of the data was performed, including a 
t-test to check whether the number of affected males is significantly different than 
the number of affected females, followed by a Fisher’s exact test to calculate the 
proportion of affected males compared to affected females. For the genetic test 
of markers associated to the trait, the functions ‘qtscore’ and ‘egscore’ from the 
GenABEL package were used (Table 1). The parameters included in the model 
were corrected until the inflation factor lambda (λ) was equal to/the closest to 1. 
Values below 1 were considered overcorrected. In all models, the fixed factor is 
disease affection status (case or control) and this parameter is called “AffStat” in 
the formula. Gender was used as a covariate in the models 2,4 and 6 (dataset 1). 
The subpopulation structure was estimated using a within sum of squares (wss) 
versus cluster graph. The population substructure (K=3) was then included in the 
models 3, 4 (dataset 1) and 2 (dataset 2). 
 The IBS for each pair of individuals i and j was computed as:  
                    f_{i,j} = Σ_k frac{(x_{i,k} - p_k) * (x_{j,k} - p_k)}{(p_k * (1 - p_k))} 
Where k changes from 1 to N number of SNPs genome wide, x_{i,k} is a 
genotype of ith individual at the kth SNP, coded as 0, 1/2, 1 and p_k is the 
frequency of the "+"  allele. This apparently provides an unbiased estimate of the 
kinship coefficient (how related the individuals in the population are to each 
other). The kinship matrix, which contained these relatedness values, was then 
determined (as returned by IBS function) and considered in the models 5,6 
(dataset 1) and 3 (dataset 2).  
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Table 1. Statistical models implemented with the different datasets. 
  Dataset 1 
1  qtscore(AffStat, data, trait= "binomial") 
2  qtscore(AffStat~sex, data, trait= "binomial") 
3  qtscore(AffStat, data, strata=pop, trait="binomial") 
4  qtscore(AffStat~sex, data, strata=pop, trait="binomial") 
5  egscore(AffStat, data, kinship=data.gkin) 
6  egscore(AffStat~sex, data, kinship=data.gkin) 
  Dataset 2 
1 qtscore(Affstat, data2, trait="binomial") 
2 qtscore(AffStat, data2, strata=pop, trait="binomial") 
3 egscore(AffStat, data2, kinship=data.gkin) 
 
The lambda was computed by regression in a Quantile-Quantile (Q-Q) plot for 
each model. The raw and the genomic control corrected p-values were plotted as 
a Manhattan plot. A Bonferroni correction limit line (-log10(0.05/nsnps) =  6.39) 
was set and added to the plot. An additional threshold (-log10(1e-05) = 5) for 
model 3 was determined based on inflated markers visualized in the Q-Q plot, 
and included in the Manhattan plot. Lastly, the top 20 SNPs according to their 
genomic control p-value (Pc1df) were summarized.  
2.2.  Resequence Analysis and polymorphism detection:   
Re-sequence data from five Great Danes (two cases and three controls) was 
available for this methodology. The data visualization was performed using the 
software IGV [18]. The software allowed an overview of the sequence quality 
(coverage and number of reads). Furthermore, this visualization allowed the 
confirmation of haplotype blocks and key SNPs that were detected in the 
previous GWAS and also the discovery of polymorphisms that segregate in 
opposite directions between cases and controls. 
The SNPs and indels were then scored by conservation across species using the 
software SeqScoring (http://www.seqscoring.net/) [19]. The genome browser 
UCSC (http://genome.ucsc.edu/) was used in order to visualize the location of 
these polymorphisms, and in this way it was determined whether they are located 
in conserved regions (exons, 5’ and 3’-UTRs, transcription factor binding sites 
and other regulatory elements). 
Finally, the “Variant Effect Predictor” tool from Ensembl 
(http://www.ensembl.org/index.html) was applied to the polymorphisms with a 
pattern score ≥3. However, pattern scores higher than 3 don’t necessarily mean 
allele segregation between the case/control groups (Table 2). Therefore, variant 
alleles exclusively found in cases (either fixed or heterozygote) for an opposite 
allele as the one found in controls, were preferred as candidates.  
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Table 2. Example of SeqScoring output showing how the relevant polymorphisms were detected. 
Example Reference Control 
1 
Control 
2 
Case 
1 
Case 
2 
*Pattern 
Score 
1 A A A G G 5 
2 G R R A A 4 
3 G R R A G 4 
*A pattern score equal to 5 and a clear segregation on case vs control was considered the best case scenario. The two 
last examples above have a pattern score equal to 4, but the last one is not segregating, meaning that pattern score 
value alone is not sufficient to determine how different cases are from controls. 
 
2.3.  PCR and Sanger Sequencing 
 
2.3.1.  Primer design:  
 
Polymorphisms matching the criteria of section 2.2 were detected in the genes 
TMC3, MESDC2, ZMAT4 and DMXL-2. In order to confirm these polymorphisms, 
PCR primers for genotyping the candidate mutations were designed using the 
Primer3 software (http://frodo.wi.mit.edu/primer3/).  
In total, 4 primer pairs were designed (Table 3). The melting temperatures of the 
primers were between 59.8°C and 61.0°C.   
         Table 3.Primers 
Primer 
Name primer sequence Chr Sense Start End 
MESDC2-U1 GTCCTGCGAGAACTTTGGTC 3 + 59569235 59569255 
MESDC2-U2 CAGTTGAGCACCCACCTTTT 3 - 59569867 59569887 
TMC3-U1 ACCACCTGCTTTGTCTCTGG 3 + 59313913 59313932 
TMC3-D1 CAGCTCACCTGTGAGTGTCC 3 - 59314394 59314413 
ZMAT4-U1 TCAGTGAGAAAGTCTGCCGTAA 16 + 27691973 27691994 
ZMAT4-D1 AAGAGCCTTGCAGAAGATGC 16 - 27692474 27692493 
DMXL2-U2 TGGGAATAAGAGTCGGAAGC 30 + 20222840 20222859 
DMXL2-D2 CTCGGATTCCTGTTGCATTT 30 - 20223492 20223511 
 
 
2.3.2.  PCR 
 
Available DNA from seven Great Danes (four cases and three controls) was used 
for the PCR and subsequent Sanger sequencing reaction. The total reaction 
volume of the PCR was 20 µl, composed of: 
Applied Biosystems 1X PCR Buffer (50 mM potassium chloride and 10 mM Tris-
HCl, pH 7,5) + MgCl2 [1.5 mM]+ dNTP[0.20µM] + primer pair [0.25 µM per primer]  
+ 0.14 µl Taq polymerase [0.035 U/µl]+ 1 ng/µl DNA and addition of milliQ water 
until the completion of the 20 µl reaction volume. PCR reactions were performed 
in Applied Biosystems 2720 Thermal Cycler machines using the program 
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represented in Figure 1. The products were then quantified on 1.5% agarose gel 
electrophoresis using standard 100bp precision marker (Fermentas).  
 
 
Figure 1. PCR cycle. 1: denaturing at 94°C for 5 minutes; 2: Touchdown cycle (-1 °C per cycle for 6 cycles) of   
denaturation, annealing and extension; 3. 30 cycles of denaturation, annealing and extension; 4. End of cycle.  
2.3.3.  Sanger sequencing reaction  
PCR products were treated with approximately 1.6 U of calf intestinal alkaline 
phosphatase (CIAP) + 2U of Exonuclease 1 (Exo1) in a 1X Exo1 Buffer 
(Fermentas). The reactions were incubated at 37°C for one hour and inactivated 
at 85°C for 15 minutes in the PCR machine. 
The PCR products with the CIAP mix were then diluted and distributed into a 
sequencing plate. Per well, each reaction contained 18 µl of total volume. It 
included 12 µl of H2O, 3 µl PCR product and 3 µl of primer (5µM). The samples 
were then submitted to the Uppsala Genome Center for sequencing.  
 
2.3.4.  Sequence Analysis 
Obtained nucleotide sequences were analyzed using the software CodonCode 
Aligner version 3.5.6 (CodonCode Corporation). The sequence ends were 
trimmed and the sequences aligned. The polymorphisms were detected and 
identified according to position (Figure 2). Also, the Dog (Canis lupus familiaris) 
genome browser UCSC BLAST tool (Broad/canFam2 assembly) was used to 
determine the exact genomic position.  
 
 
 
Figure 2. Sequence Analysis using CodonCode Aligner software. An illustrative representation of the visualization of 
two polymorphisms on TMC3 gene 
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2.4.  TaqMan genotyping: 
 
In total, 332 individuals: 178 females, 142 males, 12 unknown; 55 cases (43 
verified), 77 controls (36 verified) and 11 unknown were genotyped for five 
different polymorphisms in four genes (ZMAT4, TMC3, MESDC2 and DMXL2). 
The 332 dogs originated from nine different countries: (205 from Sweden, 6 
Finland, 48 Norway, 3 Denmark, 47 Germany, 2 The Netherlands, 1 France, 10 
USA and 10 unknown). 
The genotyping assays were designed according to custom manufacturer 
specifications (Applied Biosystems, Life technologies). 
The reaction was carried out in a 384 well plate. The total volume reaction per 
well was 5 µl, consisting of 1X of Applied Biosystems ®TaqMan Genotyping 
Master Mix ; 0.125 µl 1X Applied Biosystems ®TaqMan Genotyping Assay 
(primers + probes); 1.375 µl MQ H2O and 10 ng of DNA. A provided allelic 
discrimination guide (Appendix 2) was used. The software SDS 2.3 connected 
the machine Applied Biosystems, 7900HT Fast Real-Time PCR system 
generated the results. The cycle conditions are represented in Figure 3. 
 
Figure 3. TaqMan cycling conditions. 1. Denaturing at 95°C for 10 minutes 2. 45X 95°C for 15 seconds denaturing 
followed by annealing temperature of 60 °C for 1 minute.   
The output produced by the software SDS 2.3 was exported into a .txt and 
graphs as .png files. The allele frequencies calculations and a simple statistics: 
Student t-test and Fisher exact (2X2, 2X3 and recessive inheritance test) on the 
alternative allele frequency difference between cases and controls was 
performed using the website http://vassarstats.net/.  
 
 
3.  Results 
 
3.1.  GWAS Analysis: 
 
In total, 127 dogs (62 cases and 65 controls) composed the dataset. Where 74 
are males (23 controls and 51 cases), and 53 are females (42 controls and 11 
cases). In our data set the number of affected males is significantly different 
compared to the number of affected females, and that is proven with a simple t-
test (Table 4). A Fisher exact test was used to determine the odds ratio, which is 
approximately eight affected males for each affected female (Table 5).   
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               Table 4. t.test (H0 = true difference in means is equal to zero) 
t df p-value        95% CI 
-6.06 121.33 1.51E-08 -0.62 -0.31 
  
                                                      Table 5. Fisher exact test (H0 = true odds ratio is equal to 1) 
p-value          95% CI Odds ratio 
1.00E-07    3.46 21.31      8.30   
After the first quality control, six individuals were excluded due to high identity by 
state IBS (>=0.95): "cHD8_1004" "cHD8_1016" "cHD8_1055" "cHD8_942"  
"cHD8_951"  and "cHD8_965". The excluded dogs are actually repeated 
measures of three individuals (one male case and one female control from 
Germany and one female control from Finland).   
The subpopulations were determined. According to the wss vs cluster graph 
(Appendix 1), K is between 2 and 4. When applying K=2 or K=4 to the statistical 
models, the λ is either inflated (λ> 1.2) or overcorrected (λ<1) in comparison to 
K=3. Therefore, the number of clusters and subpopulations is more likely equal to 
3 (λ = 1.04) (Figure 4). 
 
         Figure 4: Subpopulation clusters (K=3) 
 
The proportion of cases and controls (females and males) per subpopulation 
cluster is represented in Table 6.   
Table 6. Number of cases and controls per subpopulations 1,2 and 3.                                                                                     
 Control Cases Total 
1 19(12,7) 23(6,17) 42 
2 12(7,5) 22(2,20) 34 
3 30(19,11) 15(3,12) 45 
Total 61 60 121 
*The values in parentheses are the number of females and males respectively. 
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The number of markers that were eliminated in the quality controls for the dataset 
1 is expressed in Table 7. The Table also contains the lambda(λ) values for each 
model,  and  which chromosomes contain the top 20 SNPs according to their 
genomic control p-value (Pc1df). 
        
 
Table 7. Quality control output for dataset 1 and Inflation factor λ and Chromosomes containing the top 20 associated SNPs.  
 
Model Quality 
Control 
Total 
SNPs 
Total 
SNPs 
Out 
HWE 
(X=1e-
04) 
*SNPs in 
Controls 
Out of 
HWE  
(X=1e-04) 
*SNPs in 
Cases Out 
of HWE  
(X=1e-04) 
**SNP 
with 
Low 
call 
rate 
(<95%) 
**Low 
MAF(<1e-
06%) 
*Markers out 
of HWE (P <1e-
08) 
Excluded 
Animals 
Lambd
a (λ)  
Chr 
Raw 
data  
 174375 4475 1375 3572 - - - -    
1 QC1 
 
QC2 
134300 
 
124157 
1484 
 
1113 
152 
 
0 
867 
 
824 
2351 
 
0 
34644 
 
9265 
2537 
 
877 
6 
 
0 
 
 
1.28 
15,16,171
9,20 
2  
QC2 
Same as for model 1  
1.12 
 
1,2,3,6,8,
10,11,16,
21,22,29,
30,32 
3  
QC2 
Same as for Model 1  
1.04 
15,16,17,
19,20 
4  
QC2 
 
Same as for model 1  
0.97 
1,2,3,8, 
10,21,22 
5  
QC2 
Same as for model 1  
1.11 
15,16,17,
19 
6  
QC2 
Same as for model 1  
1.05 
1,3,10,14,
19,22 
*Number of SNPs out of HWE that were still kept in the data after the quality control. 
** Number of SNPs eliminated in the quality control due to low call rate, low minor allele frequency and out of Hardy-Weinberg 
Equilibrium. 
 
 
Model 3, which included population stratification, was considered the best λ 
value (1.04) according to the analysis criteria. Model 3 is the elected model for 
determining the associated markers. No marker had a significant Bonferroni p-
value. The Q-Q plot and Manhattan plot of this model can be visualized in Figure 
3, and its corresponding top 20 SNPs are shown in Table 8.  
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Figure 5. Q-Q plot and Manhattan plot for the statistical model number 3. 
Blue line: Bonferroni corrected -log10(0.05/nsnps). Green line: -log10(1e-05). 
Blue and light blue dots: raw p-value (P1df) Red dots: genomic control p-value (Pc1df) 
 
 
Table 8. Top 20 SNPs according to the statistical model number 3. 
Marker Chr Position A1 A2 Pc1df* 
BICF2P785060 15 32998454 T C 2.54E-06 
BICF2P1365875 16 36531600 G A 2.54E-06 
BICF2S23755960 17 67326820 T C 2.54E-06 
TIGRP2P261690 19 23061287 C T 2.54E-06 
BICF2S236384 19 23071429 G A 2.54E-06 
BICF2G63042752 19 23074950 G A 2.54E-06 
BICF2G63042757 19 23094737 T C 2.54E-06 
TIGRP2P261969 19 23123709 C A 2.54E-06 
TIGRP2P262022 19 23134751 T G 2.54E-06 
BICF2P15989 19 23153883 G A 2.54E-06 
BICF2P9773 19 23181081 A C 2.54E-06 
BICF2G63042843 19 23193716 C T 2.54E-06 
TIGRP2P262674 19 23265091 C T 2.54E-06 
BICF2G63042904 19 23281246 A C 2.54E-06 
TIGRP2P262866 19 23301862 G A 2.54E-06 
TIGRP2P262902 19 23312578 A G 2.54E-06 
BICF2P137634 19 23318694 A G 2.54E-06 
TIGRP2P262951 19 23323193 G A 2.54E-06 
BICF2P12405 19 23348192 A G 2.54E-06 
BICF2G630233713 20 24868338 A G 2.54E-06 
*P-values from the 1-d.f. test for association between SNP and trait; the statistics is corrected for possible inflation 
(genomic control) 
 
The Q-Q plots and Manhattan plots for the alternative models can be visualized 
in the following Figures 6,7,8,9 and 10. The tables with the top markers can be 
found in the Appendix section. 
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Figure 6. Q-Q plot and Manhattan plot for the statistical model number 1. 
Blue line: Bonferroni corrected -log10(0.05/nsnps). Green line: -log10(1e-05). 
Blue and light blue dots: raw p-value (P1df) Red dots: genomic control p-value (Pc1df) 
 
 
 
Figure 7. Q-Q plot and Manhattan plot for the statistical model number 2. 
Blue line: Bonferroni corrected -log10(0.05/nsnps). Green line: -log10(1e-05). 
Blue and light blue dots: raw p-value (P1df) Red dots: genomic control p-value (Pc1df) 
 
 
* λ values <1 are rounded to 1 by default by the program.   
 
Figure 8. Q-Q plot and Manhattan plot for the statistical model number 4.  
Blue line: Bonferroni corrected -log10(0.05/nsnps). Green line: -log10(1e-05). 
Blue and light blue dots: raw p-value (P1df) Red dots: genomic control p-value (Pc1df) 
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Figure 9. Q-Q plot and Manhattan plot for the statistical model number 5. 
Blue line: Bonferroni corrected -log10(0.05/nsnps). Green line: -log10(1e-05). 
Blue and light blue dots: raw p-value (P1df) Red dots: genomic control p-value (Pc1df) 
 
 
Figure 10. Q-Q plot and Manhattan plot for the statistical model number 6. 
Blue line: Bonferroni corrected -log10(0.05/nsnps). Green line: -log10(1e-05). 
Blue and light blue dots: raw p-value (P1df) Red dots: genomic control p-value (Pc1df) 
 
 
The main objective of dataset 2 was to test if there were any associated markers 
on the X chromosome (chr 39). No Bonferroni significant markers were detected 
in any of the three tested models for dataset 2. This could be due to the 
insufficient number of individuals, which may have reduced the statistical power. 
In Table 9, information about the quality control of the dataset 2, λ values and 
chromosomes containing the top 20 SNPs for each value is included. The Q-Q 
and Manhattan plots and top markers are included in the appendix section. 
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Table 9. Quality control output for dataset 2, and λ values and Chromosomes containing the top 20 SNPs. 
Model Quality 
Control 
Total 
SNPs 
*Total 
SNPs 
Out of 
HWE 
(X=1e-
04) 
*SNPs in 
Controls 
Out of 
HWE  
(X=1e-
04) 
*SNPs in 
Cases 
out of 
HWE 
(X=1e-
04) 
**Low 
call rate 
(<95%) 
**Low 
MAF 
(<1e-
06%) 
*Mark
ersout 
of 
HWE 
(P <1e-
08) 
Excluded 
Animals 
   λ Chr 
1 Raw 
 
 
QC1 
174375 
 
 
130340 
3596 
 
 
579 
2427 
 
 
20 
3211 
 
 
284 
- 
 
 
2333 
- 
 
 
38373 
- 
 
 
2837 
- 
 
 
0 
 
 
 
1.07 
1,3,8,10,11, 
15,19,21,25 
26,27,30,33 
 
2  
QC1 
         
0.97 
1,11,14,15, 
19,25,29,30 
3  
QC1 
         
1.06 
1,3,11,14, 
15,19,24,25
36 
* Number of SNPs kept in the data after the quality control; 
** Number of SNPs eliminated in the quality control due to low call rate, low minor allele frequency and out of Hardy-Weinberg 
Equilibrium. 
The genetic association peak on chromosome 19 is significant (-log10(1e-05)) 
with most tested models. Two regions in chromosome 19 were also highlighted in 
the previous GWAS. The top SNPs from model 3 comprised a region between 
23.0 Mb and 23.3 Mb which was also highlighted in the previous GWAS and 
contains two 5S ribosomal RNA and is the main associated region. In Figure 11 
the distribution of the markers along chromosome 19 and their significance level 
can be observed. The peak between 23.0 Mb and 23.3 Mb is confirmed, and the 
region between 40 Mb and 60 Mb seem also to have an association peak.  
 
        Figure 11. Marker distribution along chromosome 19 
When taking a closer look as in Figure 12 and 13, it is observed that the 
associated markers are located around 23.0Mb and 23.3Mb and 44 Mb and 46 
Mb. 
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Figure 12. Marker distribution along chromosome 19 from 22.2Mb until 26.2Mb  
 
      Figure 13. Marker distribution along chromosome 19 from 44Mb until 46Mb.  
These same regions were detected in the previous GWAS and are strong 
candidate loci. There are three genes within 44Mb and 46 Mb: SPOPL, NXPH2 
and a novel transcript orthologue to LRP1B in humans. There is also a large 
intergenic region between NXPH2 and LRP1B, which can potentially harbor 
regulatory elements.  
 
3.2. Re-Sequence Analysis: Polymorphism detection: 
 
In total, 73 polymorphisms with pattern score ≥3 were detected in the re-
sequence dataset of five individuals (three controls and two cases). The Variant 
Effect Predictor tool of Ensembl was used to determine the consequence of each 
of these 73 SNPs (Table 10).  
 
Table 10. Polymorphisms and consequences. 
Chr  Synonymous Non- 
synonymous 
Intronic Intergenic/ 
Downstream 
3' UTR           
Total 
3 20 5 1 4 - 30 
16 2 1 2 10 - 15 
29 0 1 0 6 - 7 
30 5 2 1 11 2 21 
Total 27 9 4 31 2 73 
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From the 73 polymorphisms, six non-synonymous mutations were highlighted. 
The affected genes, mutation consequence, codon change, aminoacid change 
and exons where these mutations were found are listed in Table 11. 
 
Table 11. Main polymorphisms 
Chr Gene 
 
Mutation Consequence Codon change 
*Aminoacid 
   change 
Exon 
Total 
n◦ of 
exons 
3 TMC3: transmembrane channel-like 3 Non Synonymous Coding cCt /cTt 
Pro /Leu 
Exon 21 
22 
3 MESDC2:  mesoderm development candidate 2 Non Synonymous Coding Aac /Gac 
Asn /Asp 
Exon 1 
     2 
16 ZMAT4: zinc finger, matrin-type 4 Non Synonymous Coding aCc /aAc Thr /Asn Exon 3      6 
29 
Paralogue to RPL10A (self specie): ribosomal 
protein L10a Non Synonymous Coding tCt /tAt 
Ser /Tyr 
Exon 2 
     6 
30 **DMXL2: Dmx-like 2 Stop loss tCg /tAg Ser /Stop Exon 12 43/14 
30 **DMXL2: Dmx-like 2 Non Synonymous Coding aTa/aCa Ile/Thr Exon 10 43/14 
*Aminoacid change codes. Leu: Leucine, Pro: Proline, Asp: Aspartic acid, Asn: Asparagine, Thr: Threonine, Tyr: 
Tyrosine, Ser: Serine, Ile: Isoleucine. 
** DMXL2 has two transcripts. 
 
3.3.  Sanger sequence  
 
Sanger sequencing confirmed the polymorphisms in TMC3 and MESDC2 genes. 
The SNPs in ZMAT4 and DMXL2 stop loss mutation were not detected, and the 
primer pair did not cover the non-synonymous mutation in DMXL2. However, it is 
possible that the allele frequency for the non-reference allele is very low, and the 
re-sequence information supports the presence of these mutations with >3 reads 
(Appendix). TMC3, MESDC2, DMXL2 and ZMAT4 polymorphisms were 
genotyped with the TaqMan assay. However, only the non-synonymous coding 
SNP on DMXL2 was successfully genotyped due to technical problems.   
 
3.4.  TaqMan Genotyping 
 
332 individuals were genotyped for five different probe sets. The non-
synonymous mutation in DMXL2 gene was successfully genotyped in 319 
animals. The allelic discrimination plot is represented on Figure 14. The allele 
frequencies for T and C are represented on Table 12. 
 
20  
 
Figure 14. Allelic discrimination plot 
 
Table 12. Allele frequencies for DMXL2.  
 T/T T/C C/C T C p q Total nº 
individuals 
Verified Cases 24 15 4 63 23 0.73 0.26 43 
Verified Controls 26 9 1 61 11 0.84 0.15 36 
All Cases 40 30 7 110 44 0.73 0.27 77 
All Controls 27 19 4 73 27 0.71 0.28 50 
Population 142 128 49 412 226 0.64 0.35 319 
Where T/T is the number of animals homozygous for the allele T, T/C heterozygous, C/C homozygous for the allele C. 
T the total number of the allele T for each group, C the total number of the allele C for each group, p represents the 
frequency (%) of the common allele T and q is the frequency (%) of the alternative allele C. 
 
The alternative allele frequency C is slightly higher in cases as opposed to 
controls. However, a simple t-test when comparing allele frequencies between 
cases and controls shows no significance with a p-value=0.3866, and a Fisher’s 
exact test (2x3) p-value= 0.258. 
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4.  Discussion 
 
Cases of dilated cardiomyopathy (DCM) in the present data are significantly 
more prevalent in males than females, with an odds ratio approximately eight 
male cases to each female case. This is consistent with the literature [6-7]. 
However, data bias cannot be completely ruled out. No associated markers peak 
in the X chromosome were detected by the GWAS. This could be either because 
the disease in Great Danes is in fact not X-linked, or due to low statistical power. 
It can also be that there are different types of inheritance within this breed, as is 
observed in human patients [7]. The fact that the study made by Meurs et al. 
used dogs from the USA [7], while in this study the great majority of the dogs are 
European is relevant. A retrospective study on the pedigree of the animals from 
this data could help to determine the mode of inheritance. In case the disease is 
not X-linked, the male prevalence could maybe be explained by physiological 
differences and epistatic interactions with genes or copy number variants in the Y 
chromosome. In humans, males are also prevalent in heart diseases. The human 
Y chromosome was associated with risk of coronary artery disease in men of 
European ancestry, possibly through interactions of immunity and inflammation 
[20].  
 
In total, nine statistical models were approached in the GWAS. Model number 3 
included population stratification and had an inflation factor lambda equal to 1.04 
and showed association (genomic control p-value = 2.54E-06) on chromosomes 
15,16,17,19 and 20. It was noticed that when including gender to the models the 
lambda is generally deflated. It could be because this is controlling for all the 
markers that differ between males and females, and since there are more 
affected males in our data, this could take away markers that were actually 
associated to the disease, however a closer look into the data must still be 
carried out to confirm this suspicion.  
Also in model 4, when including population stratification together with gender, 
there is a slight overcorrection of the inflation factor λ=0.98. It is possible that the 
population clusters are already correcting for the gender differences, as can be 
observed in Table 6, as cluster 1 is dominated by female cases, cluster 2 by 
male cases and cluster two is gender neutral. In that way, applying structure to 
the model accounts for both the gender and genetic stratification of the data and 
by again including gender, corrects for this value twice. Different chromosomal 
peaks are observed on different models, and no bonferroni significant markers 
were present. In model 5 (Figure 9) there is one marker that is above the 
Bonferroni line, however that is the raw p-value (P1df). These factors could 
happen for different reasons, (1) there are not enough animals in the dataset for 
a good statistical power; (2) the phenotype information is not well explored; (3) 
there is data bias (not independent); (4) there are too many complex interactions 
such as epistasis; (5) confounding environmental factors, i.e; nutrition, common 
environment, physical activity, exposure to infectious diseases, stress, etc. (6) 
strict quality control leading to elimination of truly associated markers. Most of 
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these problems are difficult to solve without performing studies on environmental 
risk factors for DCM.  
 
The SNP sequence technology is still costly and the amount of genotype data is 
dependent on available funds for the research. Furthermore, a well-described 
phenotype data is critical for a good GWAS. Unfortunately it is a big challenge, 
mostly because confirmatory diagnosis relies on post-mortem histopathological 
information, and this relevant data depends highly on the dog owner/breeding 
societies cooperation. The diagnosis can also vary according to different 
veterinarians, and clinical diagnosis mistakes can happen. For this study such 
mistakes are very unlikely, since the available phenotypic data was very well 
characterized, with postmortem histopathology information, echocardiogram and 
in depth veterinary records. However, most of this extra was not included in the 
models due to the complexity of the analysis. It would be interesting to include 
information such as histopathology status, intensity of the clinical signs, age of 
onset, originating country and breeding company/owner into the GWAS analysis. 
For an accurate association and good statistical power it is ideal to use unrelated 
(independent) and balanced data, for example, an equal number of unrelated 
female and male cases. Though the data will most likely be biased when a 
disease is predominant in males and affects dogs from a breed with considerably 
low genetic variation. The analysis of the GWAS of complex polygenic diseases 
needs to be adapted and corrected for the available data, and that is the reason 
why population stratification and a kinship coefficient matrix were used in the 
statistical models for this study. A closer look into kinship matrix and a 
retrospective pedigree study can be done to determine the rate of inbreeding of 
the animals used in the database.  
Two quality controls were performed to remove markers with low call rate, low 
minor allele frequency and strongly deviating from HWE. The first control used 
the same criteria for both, cases and controls. The second quality control was 
stricter and eliminated all markers out of HWE in controls. Perhaps for this 
dataset the false discovery rate (FDR <0.2) in the control group should have not 
been applied. It could be that the risk allele is segregating lowly in controls, so 
the association signal would show up in controls instead of in cases. By 
eliminating all the markers out of HWE in controls, that signal is completely lost. 
As mentioned before, when possible, the data should be improved by adding 
more individuals, and detailed and well-characterized trait information. However, 
the more information available, more challenging the analysis is. Large datasets 
with several variables require powerful computers and complex modeling. 
Statistical and computational knowledge is required to solve the genetic 
pathways involved in complex diseases. An interesting approach for a more 
complete GWAS for a polygenic trait would include algorithms that account for 
gene-gene interactions (epistasis). There are many efforts to include epistasis 
detection in GWAS using different methodologies as described by different 
authors, using from regression, machine learning and Bayesian approaches [21-
27]. Most of these algorithms require substantial computing time in one trait, and 
an understanding of the differences between the models is important when 
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choosing which will be the best for a given data [22]. To date, very few 
publications have incorporated interaction testing in GWAS data, since it is a very 
new approach. The first exhaustive genome-wide epistasis search on a real 
dataset was performed by by Gayan et al., via their developed tool called 
“Hypothesis Free Clinical Cloning” (HFCC) on a cohort of Parkinson's disease 
patients and controls [28].  Another even more ambitious suggestion is the use of 
expert knowledge extracted from protein interaction databases. And even further, 
the use protein and gene expression data from these important structural/ion 
channel proteins as a covariate in the GWAS model, for example castalbin2 and 
triadin. This approach may facilitate the biological interpretation of the data, 
however there is still a need to develop a logical method to evaluate the 
information in these protein databases and also the metrics developed from this 
information in order to incorporate this type of expert knowledge into the analysis, 
which is another great challenge [29].  
 
Even though there are all these complicating factors, the GWAS performed in 
this study was enough to show two possibly associated regions on chromosome 
19. The regions between 23.0 and 23.3 Mb and between 44 and 46 Mb 
overlapped with the results from the previous GD GWAS. The region around 23 
Mb contains two  rRNAs, and the region between 44 and 46 Mb contains a large 
intergenic region and three genes: speckle-type POZ protein-like (SPOPL), 
neurexophilin 2 (NXPH2) and a novel transcript orthologue to the low density 
lipoprotein receptor-related protein 1B (LRP1B) in humans. None of these genes 
were previously associated to DCM or other cardiac diseases. The non-coding 
RNA may have interesting regulatory proprieties and must be further investigated 
(ref). SPOPL may be involved in ubiquitination and proteosomal degradation, and 
NXPH2 may encode signaling molecules that resemble neuropeptides. The re-
sequence data analysis on chromosome 19 included SPOPL and NXPH2 genes, 
but no relevant SNPs were found within them. All the detected polymorphisms 
that opposed between cases and controls in chr 19 fell into intergenic regions. 
Intergenic regions can potentially harbor non-coding RNA (ncRNA), long non-
coding RNA (lncRNA), cromatin markers, enhancers and copy number variants. 
ncRNAs controls the expression of target genes at the posttranscriptional level. It 
has been described as part of the “dark matter of the genome”, due to the fact 
that although we are now able to detect its presence, its function and activity 
remains poorly understood. Cromatin markers regulate epigenetic factors; 
epigenetic modifications are heritable alterations of the genome, which can 
govern gene expression without altering the DNA sequence and can be relevant 
in complex diseases [30]. The LRP1B gene may encode potential cell surface 
proteins and was not included in the re-sequence analysis. Because of the very 
large intergenic region in this chromosome, it would also be relevant to run a 
coverage analysis in order to detect possible copy number variants. Further 
analysis in both candidate regions should be carried out, with the possibility to 
discover novel genes or regulatory elements that could participate in the 
pathogenesis. No other regions detected on the previous GWAS were re-
associated. It may be because the previous analysis used smaller individual 
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database, equal quality control for cases and controls, and a different method for 
controlling population stratification. 
 
So far many negative aspects of the GWAS were highlighted. But the great 
advantage of GWAS in dogs is that they possess a large extent of linkage 
disequilibrium (LD) within breeds (distances of several megabases) and between 
breeds there is a shorter LD (over tens of kilobases)[14]. These characteristics 
represent the two bottlenecks of the modern purebred dogs (domestication and 
breed creation), which led to a high genetic variation between breeds, but low 
variation within breeds. This means that a common disease in different breeds 
can be genetically traced in two stages: genome-wide mapping of a single breed 
and subsequently narrowing the detected regions by association with the 
different breeds [14]. Newfoundland dog phenotype and SNP typing data is 
available. No overlapping regions where found between Newfoundlands and 
Great Danes. However, the Newfoundland data could be used for a second 
GWAS following similar methodology as this study, perhaps in this way some 
regions may overlap. Other dog breeds could also be used. 
 
Regarding the resequence data, non-synonymous polymorphisms within exons 
that presented allele segreation between cases and controls were detected in six 
genes. The candidate genes are: (chr3) transmembrane channel-like 3 (TMC3) 
and mesoderm development candidate 2 (MESDC2); (chr16) zinc finger, matrin-
type 4 (ZMAT4); (chr29) a paralogue to RPL10A: ribosomal protein L10a; and 
(chr 30) Dmx-like 2 (DMXL2). The IGV visualization figures of the polymorphisms 
from three control animals (011,012 and 013) and two cases (022 and 023) are 
attached to the Appendix section.    
The TMC3 gene belongs to the TMC novel family, which encodes 
transmembrane proteins. In humans,TMC3 mRNA is detected mostly in neuronal 
organs[31]. MESDC2 encodes for an assisting protein in the beta folding of low-
density lipoprotein receptors (LDLR) [32]. ZMAT4 is a zinc ion binding protein; 
RPL10A encodes for a ribosomal protein that is component of the 60S subunit 
(L10a). However the detected polymorphism is in a RPL10A paralogue, and is 
important to consider that it is typical that multiple processed pseudogenes are 
dispersed through the genome for genes encoding ribosomal proteins [33]. 
DMXL2, or its alternate name Rabonnectin-3, is a functional regulator of the 
Notch signaling pathway in mammals. Notch signaling plays an important role in 
the development and differentiation of many cell types in diverse organisms. 
Abnormal activity of the Notch pathway has been linked to several developmental 
disorders and malignant diseases [34]. Furthermore, a SNP in DMXL2 has been 
associated with ischemic stroke in afro-descendent humans [35]. Because of its 
function and two detrimental mutations within DMXL2, it is considered one of the 
main candidate genes of this study. The non-synonymous mutation was 
confirmed, however the mutation results in a stop loss in DMXL2 could not be 
confirmed in the 332 animals genotype due to technical problems.  
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The non-synonymous polymorphism on DMXL2 is located in exon 10, and 
changes an ATA codon to an ACA (isoleucine to threonine). The alternative allele 
C was slightly more frequent in cases than controls, however, this difference is 
not statistically significant with a p-value= 0.386. Even though it is not statistically 
significant, this could be because of technical mistakes during the genotyping. It 
can also be that some controls are false negatives (due to age of onset or other 
factors), or the phenotype is only expressed when other mutations are also 
present. Genetic risk penetrance should also be taken in consideration before 
completely discarding this gene as a candidate. Further evaluations should be 
made in order to check if this mutation has any participation in DCM pathology 
pathway whatsoever. A second attempt to genotype the candidate gene TMC3, 
which had been confirmed in the Sanger sequence of the 7 individuals should be 
made. In case a statistically significant mutation is finally detected, a gene 
expression study using the available tissues, as well as the functional study, 
pathways and gene interactions/regulation analysis should be carried on. 
 
The detection of the genetic basis of multifactor and complex diseases is still a 
big challenge, even with the advent of high throughput sequencing technologies. 
There are many different ways of analyzing the large amount of data generated, 
and many variables need to be considered. The validation of the candidate 
genes is no less of a challenge. It is therefore important to intertwine knowledge 
of different specialized areas (clinical diagnosis, bioinformatics, statistics, 
biological pathways, among others) to achieve the goal of understanding the 
genetics of DCM. 
 
 
5. Conclusion 
 
The current GWAS methodology showed a genomic re-association of two 
regions on chromosome 19 (23.0-23.3Mb and 44-46Mb) to Great Dane DCM. No 
other regions were re-associated. Both regions may contain potential novel 
genes and regulatory factors that can possibly be involved in the GD DCM 
etiology pathway. From the Illumina re-sequencing data, six candidate mutations 
in five different genes were detected. A non-synonymous mutation in DMXL2 
was confirmed through the successful genotyping of 319 individuals. The 
alternative allele was slightly more frequent in cases than controls, however not 
statistically significant (p-value=0.38). Further investigation of the detected 
candidate mutations and regions, and the addition of extra phenotype information 
and consideration of gene-gene interactions in a GWAS should be carried out in 
future studies in order to determine the relevance of the present findings.  
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